Literature DB >> 15690331

The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion.

Annika Dejmek1, Anders Hjerpe.   

Abstract

A previously tested antibody panel identified three criteria of major importance for distinguishing between mesothelioma and adenocarcinoma (ACA): carcinoembryonic antigen (CEA), BerEp4, and epithelial membrane antigen (EMA) accentuated at the cell membrane. An extended panel, consisting of CEA, BerEp4, EMA, vimentin, mesothelioma antibody (HBME-1), thrombomodulin, Ca125, and sialyl-Tn was applied to effusions from 86 ACAs and 21 mesotheliomas. The specificities and sensitivities of the previously identified reactivity patterns were tested on the new material and the effect of the added antibodies was evaluated. Further, hyaluronan analysis was added as a parameter. The previously selected criteria remained fully predictive for mesothelioma and ACA, respectively, also in the extended material (in all, 139 ACAs and 57 mesotheliomas). With the addition of the hyaluronan value, 79% of the cases was identified with 100% specificity. Among the new antibodies sialyl-Tn seemed the most promising because it specifically identified ACAs not expressing CEA. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15690331     DOI: 10.1002/dc.20202

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  6 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

2.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

3.  Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.

Authors:  Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

4.  Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.

Authors:  Adam Szulkin; Rita Otvös; Carl-Olof Hillerdal; Aytekin Celep; Eviane Yousef-Fadhel; Henriette Skribek; Anders Hjerpe; László Székely; Katalin Dobra
Journal:  BMC Cancer       Date:  2014-09-24       Impact factor: 4.430

5.  Diagnostic accuracy of Ber-EP4 for metastatic adenocarcinoma in serous effusions: a meta-analysis.

Authors:  Bo Wang; Diandian Li; Xuemei Ou; Qun Yi; Yulin Feng
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

6.  Multiplex Soluble Biomarker Analysis from Pleural Effusion.

Authors:  Joman Javadi; Katalin Dobra; Anders Hjerpe
Journal:  Biomolecules       Date:  2020-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.